Investigation on the medication compliance of patients with chronic hepatitis B receiving free Entecavir
TAO Junxiu1,2 LI Xiaodong1,2 WAN Changxiu1,2 WANG Hui1,2 WU Huikun1,2 ZHOU Qiong1,2 LIANG Haili1,2 WANG Ting1,2
1.Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Hubei Province Academy of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China
Abstract:Objective To investigate status of the medication compliance of patients with chronic hepatitis B receiving free Entecavir. Methods A total of 401 patients with chronic hepatitis B receiving free Entecavir and participated in the clinical study of Hubei Provincial Hospital of Traditional Chinese Medicine from June 2012 to April 2016 were taken as objects, followed-up for 48 weeks, the investigation and quality control was conducted according to the dose of drug use and the amount of drug recovery from the patients' medication log card, so as to evaluate the medication compliance of patients. Results The medication compliance of 24, 36 weeks in patients with chronic hepatitis B was better than those of 12, 48 weeks (P < 0.01). The compliance rate of one year was 98.4%, full compliance was accounted for 32.0%, and the percentage of compliance >95% d was 92.4%. The medication compliance of patients with hepatitis B cirrhosis was better than that of mild to moderate chronic hepatitis B (P < 0.01). The main reason of missing drugs was forgotten. Conclusion Although the medication compliance of patients with chronic hepatitis B receiving free Entecavir is high, but the patients still lack the knowledge about the disease. It is necessary to strengthen the patients' cognitive education of the disease and improve the compliance.
陶军秀1,2 李晓东1,2 万长秀1,2 王晖1,2 吴辉坤1,2 周琼1,2 梁海莉1 汪婷1,2 . 慢性乙型肝炎患者免费恩替卡韦服药依从性水平调查[J]. 中国医药导报, 2017, 14(35): 37-40.
TAO Junxiu1,2 LI Xiaodong1,2 WAN Changxiu1,2 WANG Hui1,2 WU Huikun1,2 ZHOU Qiong1,2 LIANG Haili1,2 WANG Ting1,2. Investigation on the medication compliance of patients with chronic hepatitis B receiving free Entecavir. 中国医药导报, 2017, 14(35): 37-40.